Table 3 Dose modifications for tafasitamab and lenalidomide hematologic toxicities.
From: Diffuse large B-cell lymphoma: new targets and novel therapies
Event | Dose modification |
|---|---|
Platelet count ≤50,000/µl | Hold tafasitamab and lenalidomide and monitor counts weekly until platelet count is ≥50,000/µl |
Neutrophil count ≤1000/µl for at least 7 days or febrile neutropenia or neutrophil count ≤500/µl | Hold tafasitamab and lenalidomide and monitor counts weekly until neutrophil count is ≥1000/µl |
